Literature DB >> 17381074

Role of lysine187 within the second extracellular loop of the type A cholecystokinin receptor in agonist-induced activation. Use of complementary charge-reversal mutagenesis to define a functionally important interdomain interaction.

Maoqing Dong1, Xi-Qin Ding, Scott E Thomas, Fan Gao, Polo C-H Lam, Ruben Abagyan, Laurence J Miller.   

Abstract

Activation of guanine nucleotide-binding protein (G protein)-coupled receptors is believed to involve conformational change that exposes a domain for G protein coupling at the cytosolic surface of the helical confluence, although the mechanisms for achieving this are not well understood. This conformational change can be achieved by docking a diverse variety of agonist ligands, known to occur by interacting with different regions of these receptors. In this study, we focus on the importance of a specific basic residue (Lys187) within the second extracellular loop of the receptor for the peptide hormone, cholecystokinin. Alanine-replacement and charge-reversal mutagenesis of this residue showed that it had no effect on the binding of natural peptide and nonpeptidyl ligands of this receptor but markedly interfered with agonist-stimulated signaling. It was demonstrated that this negative effect on biological activity could be eliminated with the truncation of the first 30 residues of the amino-terminal tail of this receptor. Complementary charge-reversal mutagenesis of each of the five conserved acidic residues within this region of the receptor in the presence of the charge-reversed Lys187 revealed that only the Asp5 mutant fully reversed the negative functional impact of the Lys187 charge reversal. Thus, we have demonstrated that a basic residue within the second extracellular loop of the cholecystokinin receptor interacts with a specific acidic residue within the amino terminus of this receptor. This residue-residue interaction is nicely accommodated within a new molecular model of the agonist-occupied cholecystokinin receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17381074      PMCID: PMC2580722          DOI: 10.1021/bi0622468

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

1.  Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.

Authors:  Kaleeckal G Harikumar; Delia I Pinon; William S Wessels; Eric S Dawson; Terry P Lybrand; Franklyn G Prendergast; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2004-01       Impact factor: 4.436

2.  Correlated mutation analyses on very large sequence families.

Authors:  L Oliveira; A C M Paiva; G Vriend
Journal:  Chembiochem       Date:  2002-10-04       Impact factor: 3.164

3.  Sequence analysis reveals how G protein-coupled receptors transduce the signal to the G protein.

Authors:  Laerte Oliveira; Paulo B Paiva; Antonio C M Paiva; Gerrit Vriend
Journal:  Proteins       Date:  2003-09-01

4.  Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.

Authors:  V Gigoux; B Maigret; C Escrieut; S Silvente-Poirot; M Bouisson; J A Fehrentz; L Moroder; D Gully; J Martinez; N Vaysse; A D Fourmy
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

5.  Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.

Authors:  Elizabeth M Hadac; Eric S Dawson; James W Darrow; Elizabeth E Sugg; Terry P Lybrand; Laurence J Miller
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

6.  Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe.

Authors:  X Q Ding; V Dolu; E M Hadac; E L Holicky; D I Pinon; T P Lybrand; L J Miller
Journal:  J Biol Chem       Date:  2000-10-24       Impact factor: 5.157

7.  Molecular complex of cholecystokinin-8 and N-terminus of the cholecystokinin A receptor by NMR spectroscopy.

Authors:  M Pellegrini; D F Mierke
Journal:  Biochemistry       Date:  1999-11-09       Impact factor: 3.162

8.  Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor.

Authors:  Xi-Qin Ding; Delia I Pinon; Kristina E Furse; Terry P Lybrand; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2002-05       Impact factor: 4.436

9.  Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.

Authors:  Sonnet J H Arlander; Maoqing Dong; Xi-Qin Ding; Delia I Pinon; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2004-09       Impact factor: 4.436

10.  Disulfide bond structure and accessibility of cysteines in the ectodomain of the cholecystokinin receptor: specific mono-reactive receptor constructs examine charge-sensitivity of loop regions.

Authors:  Xi-Qin Ding; Vesile Dolu; Elizabeth M Hadac; Michael Schuetz; Laurence J Miller
Journal:  Receptors Channels       Date:  2003
View more
  8 in total

1.  The micelle-associated 3D structures of Boc-Y(SO3)-Nle-G-W-Nle-D-2-phenylethylester (JMV-180) and CCK-8(s) share conformational elements of a calculated CCK1 receptor-bound model.

Authors:  Mohanraja Kumar; Joseph R Reeve; Weidong Hu; Laurence J Miller; David A Keire
Journal:  J Med Chem       Date:  2008-06-10       Impact factor: 7.446

2.  Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.

Authors:  Maoqing Dong; Ashton M Vattelana; Polo C-H Lam; Andrew J Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; David R Haines; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2014-10-15       Impact factor: 4.436

3.  Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.

Authors:  Maoqing Dong; Polo C-H Lam; Delia I Pinon; Ruben Abagyan; Laurence J Miller
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

4.  Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor.

Authors:  Fan Gao; Patrick M Sexton; Arthur Christopoulos; Laurence J Miller
Journal:  Bioorg Med Chem Lett       Date:  2008-06-20       Impact factor: 2.823

5.  Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor.

Authors:  Nieves Gonzalez; Simon J Hocart; Sergio Portal-Nuñez; Samuel A Mantey; Tomoo Nakagawa; Enrique Zudaire; David H Coy; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2007-11-15       Impact factor: 4.030

6.  Effects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulation.

Authors:  S Vincent Wu; Kaleeckal G Harikumar; Rebecca J Burgess; Joseph R Reeve; Laurence J Miller
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09       Impact factor: 4.052

Review 7.  Structural basis of cholecystokinin receptor binding and regulation.

Authors:  Laurence J Miller; Fan Gao
Journal:  Pharmacol Ther       Date:  2008-05-11       Impact factor: 12.310

8.  Sensitivity of cholecystokinin receptors to membrane cholesterol content.

Authors:  Aditya J Desai; Laurence J Miller
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-18       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.